Lombardi M, Pizzarelli F, Righi M, Cerrai T, Dattolo P, Nigrelli S, Michelassi S, Sisca S, Alecci A, Di Geronimo P
Nephrology and Dialysis Unit, S.M. Annunziata Hospital, Florence, Italy.
Nephron. 1992;61(3):266-8. doi: 10.1159/000186900.
35 dialysis patients underwent anti-HBV vaccination. We classified patients in responders or non-responders using an anti-HBs titer of 50 UI/l as the discriminating serum level and tried to assess whether the antibody response bears any relationship with the nutritional status. 26 patients (74%) reached the target atb titer, which was maintained during follow-up (average 360 UI/l). The weak response in the other 9, with values never exceeding 20 UI/l, was short-lived. Anthropometric and impedenziometric parameters were higher in responders than in nonresponders, but the difference did not reach statistical significance. We conclude that the atb titer which discriminates uremics in responders or not must be greater than 50 UI/l and that the nutritional status may interfere with the seroconversion rate, but this conclusion needs to be validated in a wider population.
35名透析患者接受了抗乙肝病毒疫苗接种。我们以50 UI/l的抗-HBs滴度作为区分血清水平，将患者分为应答者或无应答者，并试图评估抗体反应是否与营养状况有关。26名患者（74%）达到了目标抗-HBs滴度，且在随访期间保持稳定（平均360 UI/l）。其他9名患者反应较弱，滴度从未超过20 UI/l，且持续时间较短。应答者的人体测量和阻抗测量参数高于无应答者，但差异未达到统计学意义。我们得出结论，区分尿毒症患者是否为应答者的抗-HBs滴度必须大于50 UI/l，营养状况可能会干扰血清转化率，但这一结论需要在更广泛的人群中得到验证。
